Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment - Tabular View

Tracking Information
First Received Date ^ICMJE	September 7, 2005
Last Updated Date	January 28, 2008
Start Date ^ICMJE	September 2005
Primary Completion Date
Current Primary Outcome Measures ^ICMJE (submitted: September 7, 2005)	Comparison of KW-3902IV alone or with loop diuretic on renal function.
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT00159614 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Official Title ^ICMJE	Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment
Brief Summary	The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety Study
Condition ^ICMJE	Heart Failure, Congestive Renal Insufficiency
Intervention ^ICMJE	Drug: KW-3902IV
Study Arms / Comparison Groups
Publications *	Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007 Oct;13(8):609-17.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	30
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Stable congestive heart failure Impaired renal function Taking oral loop diuretic Exclusion Criteria: Acutely decompensated (unstable) and end stage heart failure Diuretics other than loop diuretics Pregnant or nursing Inability to follow instructions Participation in another clinical trial within past 30 days
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00159614
Responsible Party
Study ID Numbers ^ICMJE	CKI-203
Study Sponsor ^ICMJE	NovaCardia
Collaborators ^ICMJE	Merck
Investigators ^ICMJE
Information Provided By	NovaCardia
Verification Date	January 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP